1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
3. INTRODUCTION
3.1. Chapter Overview
3.2. Drug Discovery and Development Timelines
3.3. Overview of In Silico Drug Discovery Tools
3.3.1. Historical Evolution of the In Silico Approach
3.3.2. Comparison of Traditional Drug Discovery Approaches and In Silico / Computer Aided Methods
3.3.3. In Silico / Computed Aided Approaches for Drug Design and Development
3.4. Applications of In Silico Tools in the Drug Discovery Process
3.4.1. Target Identification
3.4.1.1. Chemoinformatics-based Tools
3.4.1.2. Network-based Drug Discovery
3.4.1.3. Computational Platforms and Interaction Repositories
3.4.2. Target Validation
3.4.3. Hit Generation
3.4.3.1. High-Throughput Screening
3.4.3.2. Fragment Based Screening
3.4.3.3. Virtual Screening
3.4.4. Hit-to-Lead
3.4.4.1. Pharmacodynamics and Pharmacokinetics Modeling
3.4.4.2. Other Novel Approaches
3.4.5. Lead Optimization
3.4.5.1. Pharmacophore Modeling
3.4.5.2. Docking
3.4.5.3. Structure Activity Relationships (SAR) / Quantitative Structure Activity Relationship (QSAR)
3.4.5.4. Molecular Modeling
3.5. Advantages of using In Silico Tools for Drug Discovery
3.6. Challenges Associated with Conducting In Silico Drug Discovery Operations
3.7. Anticipated Rise in Outsourcing In Silico Drug Discovery Operations
3.8. Concluding Remarks
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. In Silico Drug Discovery Services for Large Molecules: List of Industry Players
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Company Size and Location of Headquarters
4.2.5. Analysis by Type of Business Model
4.2.6. Analysis by Drug Discovery Steps
4.2.7. Analysis by Type of Large Molecule
4.2.7.1. Analysis by Type of Antibody
4.2.7.2. Analysis by Type of Protein
4.2.8. Analysis by Type of In Silico Approach Used
4.2.9. Analysis by Types of In Silico Services Offered
4.2.10. Analysis by Type of Clientele
4.3. In Silico Drug Discovery Services: List of Software / Technologies
4.4. In Silico Drug Discovery Services: List of Consulting and Training Service Providers
5. KEY INSIGHTS
5.1. Chapter Overview
5.2. Logo Landscape: Analysis by Company Size and Location of Headquarters
5.3. Tree Map Representation: Analysis by Company Size and Drug Discovery Steps
5.4. World Map Representation: Regional Analysis of Outsourcing Activity
5.5. Grid Representation: Analysis by Type of Large Molecule, In Silico Approach Used and Type of Clientele
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Leading Players Based in North America
6.2.1. BioDuro
6.2.1.1. Company Overview
6.2.1.2. Funding and Investment Information
6.2.1.3. In Silico-based Service Portfolio
6.2.1.4. Recent Developments and Future Outlook
6.2.1.5. Company Benchmarking Output
6.2.2. Creative Biostructure
6.2.2.1. Company Overview
6.2.2.2. Funding and Investment Information
6.2.2.3. In Silico-based Service Portfolio
6.2.2.4. Recent Developments and Future Outlook
6.2.2.5. Company Benchmarking Output
6.2.3. GenScript
6.2.3.1. Company Overview
6.2.3.2. Funding and Investment Information
6.2.3.3. In Silico-based Service Portfolio
6.2.3.4. Recent Developments and Future Outlook
6.2.3.5. Company Benchmarking Output
6.2.4. LakePharma
6.2.4.1. Company Overview
6.2.4.2. Funding and Investment Information
6.2.4.3. In Silico-based Service Portfolio
6.2.4.4. Recent Developments and Future Outlook
6.2.4.5. Company Benchmarking Output
6.3. Leading Players Based in Europe
6.3.1. Abzena
6.3.1.1. Company Overview
6.3.1.2. Funding and Investment Information
6.3.1.3. In Silico-based Service Portfolio
6.3.1.4. Recent Developments and Future Outlook
6.3.1.5. Company Benchmarking Output
6.3.2. BioNTech
6.3.2.1. Company Overview
6.3.2.2. Funding and Investment Information
6.3.2.3. In Silico-based Service Portfolio
6.3.2.4. Recent Developments and Future Outlook
6.3.2.5. Company Benchmarking Output
6.3.3. Sygnature Discovery
6.3.3.1. Company Overview
6.3.3.2. Funding and Investment Information
6.3.3.3. In Silico-based Service Portfolio
6.3.3.4. Recent Developments and Future Outlook
6.3.3.5. Company Benchmarking Output
6.4. Leading Players Based in Asia-Pacific
6.4.1. ChemPartner
6.4.1.1. Company Overview
6.4.1.2. In Silico-based Service Portfolio
6.4.1.3. Recent Developments and Future Outlook
6.4.1.4. Company Benchmarking Output
6.4.2. Sundia MediTech
6.4.2.1. Company Overview
6.4.2.2. Funding and Investment Information
6.4.2.3. In Silico-based Service Portfolio
6.4.2.4. Recent Development and Future Outlook
6.4.2.5. Company Benchmarking Output
6.4.3. Viva Biotech
6.4.3.1. Company Overview
6.4.3.2. Funding and Investment Information
6.4.3.3. In Silico-based Service Portfolio
6.4.3.4. Recent Development and Future Outlook
6.4.3.5. Company Benchmarking Output
7. COMPANY COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.2. Key Assumptions and Methodology
7.3. Company Competitiveness Analysis: In Silico Drug Discovery Service Providers in North America
7.4. Company Competitiveness Analysis: In Silico Drug Discovery Service Providers in Europe
7.5. Company Competitiveness Analysis: In Silico Drug Discovery Service Providers in Asia-Pacific and Rest of the World
8. KEY OPPORTUNITY AREAS
8.1. Chapter Overview
8.2. Key Assumptions and Methodology
8.3. Antibodies
8.3.1. Developer Landscape
8.3.1.1. Number of Pipeline Molecules
8.3.1.2. Affiliated Market Size and Growth Rate
8.3.2. In Silico Service Providers for Antibodies: 3D Bubble Analysis Based on Number of Drug Discovery Steps, Strength of Service Portfolio and Company Size
8.4. Cell Therapies
8.4.1 Developer Landscape
8.4.1.1 Number of Pipeline Molecules
8.4.1.2 Affiliated Market Size and Growth Rate
8.4.2. In Silico Service Providers for Cell Therapies: 3D Bubble Analysis Based on Number of Drug Discovery Steps, Strength of Service Portfolio and Company Size
8.5. Gene Therapies
8.5.1 Developer Landscape
8.5.1.1 Number of Pipeline Molecules
8.5.1.2 Affiliated Market Size and Growth Rate
8.5.2. In Silico Service Providers for Gene Therapies: 3D Bubble Analysis Based on Number of Drug Discovery Steps, Strength of Service Portfolio and Company Size
8.6. Nucleic Acids
8.6.1 Developer Landscape
8.6.1.1 Number of Pipeline Molecules
8.6.1.2 Affiliated Market Size and Growth Rate
8.6.2. In Silico Service Providers for Nucleic Acids: 3D Bubble Analysis Based on Number of Drug Discovery Steps, Strength of Service Portfolio and Company Size
8.7. Peptides
8.7.1. Developer Landscape
8.7.1.1. Number of Pipeline Molecules
8.7.1.2. Affiliated Market Size and Growth Rate
8.7.2. In Silico Service Providers for Peptides: 3D Bubble Analysis Based on Number of Drug Discovery Steps, Strength of Service Portfolio and Company Size
8.8. Proteins
8.8.1. Developer Landscape
8.8.1.1. Number of Pipeline Molecules
8.8.1.2. Affiliated Market Size and Growth Rate
8.8.2. In Silico Service Providers for Proteins: 3D Bubble Analysis Based on Number of Drug Discovery Steps, Strength of Service Portfolio and Company Size
8.9. Vectors
8.9.1 Developer Landscape
8.9.1.1 Number of Pipeline Molecules
8.9.1.2 Affiliated Market Size and Growth Rate
8.9.2. In Silico Service Providers for Vectors: 3D Bubble Analysis Based on Number of Drug Discovery Steps, Strength of Service Portfolio and Company Size
9. EMERGING BUSINESS MODELS AND STRATEGIES
9.1. Chapter Overview
9.2. Key Assumptions and Methodology
9.3. In Silico Service Providers: Analysis by Number of Large Molecules and Drug Discovery Steps Covered
9.3.1. Strategies for Short Term Success
9.3.2. Strategies for Long Term Success
9.4. Concluding Remarks
10. CASE STUDY: COMPARISON OF DRUG DISCOVERY PROCESSES OF SMALL MOLECULES AND LARGE MOLECULES
10.1. Chapter Overview
10.2. Small Molecule and Large Molecule Drugs
10.2.1. Comparison of Key Specifications
10.2.2. Comparison of Manufacturing Processes
10.2.3. Comparison of Drug Discovery Processes
10.3. Approaches to Improve Discovery Process of Large Molecules
11. SURVEY ANALYSIS
11.1. Chapter Overview
11.2. Overview of Respondents
11.2.1. Seniority Level of Respondents
11.3. Survey Insights
11.3.1. Drug Discovery Steps
11.3.2. Type of Large Molecules
11.3.3. In Silico Service Portfolio
11.3.4. Likely Adoption of In Silico Tools for Large Molecules Drug Discovery
11.3.5. Current Market Opportunity
11.3.6. Cost Saving Potential of the In Silico Approach
12. COST SAVING ANALYSIS
12.1. Chapter Overview
12.2. Key Assumptions
12.3. Scope and Methodology
12.4. Overall Cost Saving Potential of In Silico Tools in Large Molecule Drug Discovery, 2020-2030
12.5. Concluding Remarks
13. MARKET FORECAST
13.1. Chapter Overview
13.2. Forecast Methodology and Key Assumptions
13.3. Overall In Silico Drug Discovery Services Market for Large Molecules, 2020-2030
13.3.1. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Drug Discovery Steps, 2020-2030
13.3.1.1. In Silico Drug Discovery Services Market for Large Molecules: Share of Target Identification, 2020-2030
13.3.1.2. In Silico Drug Discovery Services Market for Large Molecules: Share of Target Validation, 2020-2030
13.3.1.3. In Silico Drug Discovery Services Market for Large Molecules: Share of Hit Generation, 2020-2030
13.3.1.4. In Silico Drug Discovery Services Market for Large Molecules: Share of Hit-to-Lead, 2020-2030
13.3.1.5. In Silico Drug Discovery Services Market for Large Molecules: Share of Lead Optimization, 2020-2030
13.3.2. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Type of Large Molecule, 2020-2030
13.3.2.1. In Silico Drug Discovery Services Market for Large Molecules: Share of Antibodies, 2020-2030
13.3.2.2. In Silico Drug Discovery Services Market for Large Molecules: Share of Proteins, 2020-2030
13.3.2.3. In Silico Drug Discovery Services Market for Large Molecules: Share of Peptides, 2020-2030
13.3.2.4. In Silico Drug Discovery Services Market for Large Molecules: Share of Nucleic Acids, 2020-2030
13.3.2.5. In Silico Drug Discovery Services Market for Large Molecules: Share of Vectors, 2020-2030
13.3.3. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Company Size, 2020-2030
13.3.3.1. In Silico Drug Discovery Services Market for Large Molecules: Share of Small Companies, 2020-2030
13.3.3.2. In Silico Drug Discovery Services Market for Large Molecules: Share of Mid-sized Companies, 2020-2030
13.3.3.3. In Silico Drug Discovery Services Market for Large Molecules: Share of Large Companies, 2020-2030
13.3.4. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Therapeutic Area, 2020-2030
13.3.4.1. In Silico Drug Discovery Services Market for Large Molecules: Share of Autoimmune Disorders, 2020-2030
13.3.4.2. In Silico Drug Discovery Services Market for Large Molecules: Share of Blood Disorders, 2020-2030
13.3.4.3. In Silico Drug Discovery Services Market for Large Molecules: Share of Cardiovascular Disorders, 2020-2030
13.3.4.4. In Silico Drug Discovery Services Market for Large Molecules: Share of Gastrointestinal and Digestive Disorders, 2020-2030
13.3.4.5. In Silico Drug Discovery Services Market for Large Molecules: Share of Hormonal Disorders, 2020-2030
13.3.4.6. In Silico Drug Discovery Services Market for Large Molecules: Share of Human Immunodeficiency Virus (HIV) / Acquired Immunodeficiency Syndrome (AIDS), 2020-2030
13.3.4.7. In Silico Drug Discovery Services Market for Large Molecules: Share of Infectious Diseases, 2020-2030
13.3.4.8. In Silico Drug Discovery Services Market for Large Molecules: Share of Metabolic Disorders, 2020-2030
13.3.4.9. In Silico Drug Discovery Services Market for Large Molecules: Share of Mental Disorders, 2020-2030
13.3.4.10. In Silico Drug Discovery Services Market for Large Molecules: Share of Musculoskeletal Disorders, 2020-2030
13.3.4.11. In Silico Drug Discovery Services Market for Large Molecules: Share of Neurological Disorders, 2020-2030
13.3.4.12. In Silico Drug Discovery Services Market for Large Molecules: Share of Oncological Disorders 2020-2030
13.3.4.13. In Silico Drug Discovery Services Market for Large Molecules: Share of Respiratory Disorders, 2020-2030
13.3.4.13. In Silico Drug Discovery Services Market for Large Molecules: Share of Skin Disorders, 2020-2030
13.3.4.14. In Silico Drug Discovery Services Market for Large Molecules: Share of Urogenital Disorders, 2020-2030
13.3.4.15. In Silico Drug Discovery Services Market for Large Molecules: Share of Others, 2020-2030
13.3.5. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Type of Sponsor, 2020-2030
13.3.5.1. In Silico Drug Discovery Services Market for Large Molecules: Share of Industry Players, 2020-2030
13.3.5.2. In Silico Drug Discovery Services Market for Large Molecules: Share of Non-Industry Players, 2020-2030
13.3.6. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Key Geographical Regions, 2020-2030
13.3.6.1. In Silico Drug Discovery Services Market for Large Molecules: Share of North America, 2020-2030
13.3.6.1.1. In Silico Drug Discovery Services Market for Large Molecules: Share of US, 2020-2030
13.3.6.1.2. In Silico Drug Discovery Services Market for Large Molecules: Share of Canada, 2020-2030
13.3.6.2. In Silico Drug Discovery Services Market for Large Molecules: Share in Europe, 2020-2030
13.3.6.2.1. In Silico Drug Discovery Services Market for Large Molecules: Share in Germany, 2020-2030
13.3.6.2.2. In Silico Drug Discovery Services Market for Large Molecules: Share in France, 2020-2030
13.3.6.2.3. In Silico Drug Discovery Services Market for Large Molecules: Share in the UK, 2020-2030
13.3.6.2.4. In Silico Drug Discovery Services Market for Large Molecules: Share in Italy, 2020-2030
13.3.6.2.5. In Silico Drug Discovery Services Market for Large Molecules: Share in Spain, 2020-2030
13.3.6.2.6. In Silico Drug Discovery Services Market for Large Molecules: Share in Rest of Europe, 2020-2030
13.3.6.3. In Silico Drug Discovery Services Market for Large Molecules: Share in Asia-Pacific and Rest of the World, 2020-2030
13.3.6.3.1. In Silico Drug Discovery Services Market for Large Molecules: Share in China, 2020-2030
13.3.6.3.2. In Silico Drug Discovery Services Market for Large Molecules: Share in India, 2020-2030
13.3.6.3.3. In Silico Drug Discovery Services Market for Large Molecules: Share in Japan, 2020-2030
14. IN SILICO TOOLS AND UPCOMING TRENDS IN DRUG DISCOVERY
14.1. Chapter Overview
14.2. Owing to Potential Cost and Time-related Benefits, Outsourcing of Drug Discovery Operations is Expected to Increase in the Future
14.3. Technological Advancements are Likely to Revolutionize the Current Drug Discovery Processes
14.3.1. Integration of Artificial Intelligence in the Drug Discovery Process is Expected to Improve the Overall Efficiency and Productivity
14.3.2. Increased Adoption of Cloud Based Technology Platforms is Anticipated to Enhance the Scalability and Flexibility of the Drug Discovery Process
14.3.3. Rising Interest in Use of Force Fields for In Silico Drug Discovery
14.4. Concluding Remarks
15. EXECUTIVE INSIGHTS
15.1. Chapter Overview
15.2. ProSciens
15.2.1. Company Snapshot
15.2.2. Interview Transcript: Edelmiro Moman, Founder and Chief Executive Officer
15.3. Conifer Point Pharmaceuticals
15.3.1. Company Snapshot
15.3.2. Interview Transcript: John L Kulp, Chief Executive Officer and Chief Technical Officer
15.4. Evotec
15.4.1. Company Snapshot
15.4.2. Interview Transcript: Mark Whittaker, Senior Vice President, Drug Discovery
15.5. Candidum
15.5.1. Company Snapshot
15.5.2. Interview Transcript: Sven Benson, Founder
List Of Figures
Figure 3.1. Drug Discovery and Development Timeline
Figure 3.2. Historical Evolution of Computational Drug Discovery Approaches
Figure 3.3. Steps Involved in the Virtual Drug Discovery Process
Figure 3.4. Comparison of Traditional and In Silico Drug Discovery Approaches
Figure 3.5. Classification of In Silico Drug Discovery Approaches
Figure 3.6. Flowchart of the In Silico Drug Discovery Approach
Figure 3.7. In Silico Drug Discovery Service Map
Figure 3.8. Advantages of using In Silico Drug Discovery Services
Figure 3.9. Types of Large Molecule Drugs
Figure 4.1. In Silico Drug Discovery Services for Large Molecules: Distribution by Year of Establishment
Figure 4.2. In Silico Drug Discovery Services for Large Molecules: Distribution by Company Size
Figure 4.3. In Silico Drug Discovery Services for Large Molecules: Distribution by Location of Headquarters
Figure 4.4. In Silico Drug Discovery Services for Large Molecules: Distribution by Type of Business Model
Figure 4.5. In Silico Drug Discovery Services for Large Molecules: Distribution by Drug Discovery Steps
Figure 4.6. In Silico Drug Discovery Services for Large Molecules: Distribution by Type of Large Molecule
Figure 4.7. In Silico Drug Discovery Services for Large Molecules: Distribution by Type of Antibody
Figure 4.8. In Silico Drug Discovery Services for Large Molecules: Distribution by Type of Protein
Figure 4.9. In Silico Drug Discovery Services for Large Molecules: Distribution by Type of In Silico Approach Used
Figure 4.10. In Silico Drug Discovery Services for Large Molecules: Distribution by Types of In Silico Services Offered
Figure 5.1. Logo Landscape: Distribution by Company Size and Location of Headquarters
Figure 5.2. Tree Map Representation: Distribution by Company Size and Drug Discovery Steps
Figure 5.3. World Map Representation: Regional Analysis of Outsourcing Activity
Figure 5.4. Grid Representation: Distribution by Type of Large Molecule, Designing Approach Used and Type of Clientele
Figure 6.1. BioDuro: In Silico-based Service Portfolio
Figure 6.2. BioDuro: Peer Group Benchmark Comparison
Figure 6.3. Creative Biostructure: In Silico-based Service Portfolio
Figure 6.4. Creative Biostructure: Peer Group Benchmark Comparison
Figure 6.5. GenScript: In Silico-based Service Portfolio
Figure 6.6. GenScript: Peer Group Benchmark Comparison
Figure 6.7. LakePharma: In Silico-based Service Portfolio
Figure 6.8. LakePharma: Peer Group Benchmark Comparison
Figure 6.9. Abzena: In Silico-based Service Portfolio
Figure 6.10. Abzena: Company Benchmarking Output
Figure 6.11. BioNTech: In Silico-based Service Portfolio
Figure 6.12. BioNTech: Peer Group Benchmark Comparison
Figure 6.13. Sygnature Discovery: In Silico-based Service Portfolio
Figure 6.14. Sygnature Discovery: Peer Group Benchmark Comparison
Figure 6.15. ChemPartner: In Silico-based Service Portfolio
Figure 6.16. ChemPartner: Peer Group Benchmark Comparison
Figure 6.17. Sundia MediTech: In Silico-based Service Portfolio
Figure 6.18. Sundia MediTech: Peer Group Benchmark Comparison
Figure 6.19. Viva Biotech: In Silico-based Service Portfolio
Figure 6.20. Viva Biotech: Peer Group Benchmark Comparison
Figure 7.1. Company Competitiveness Analysis: In Silico Drug Discovery Service Providers in North America
Figure 7.2. Company Competitiveness Analysis: In Silico Drug Discovery Service Providers in Europe
Figure 7.3. Company Competitiveness Analysis: In Silico Drug Discovery Service Providers in Asia-Pacific and Rest of the World
Figure 8.1. In Silico Drug Discovery Service Providers for Antibodies: 3D Bubble Representation
Figure 8.2. In Silico Drug Discovery Service Providers for Cell Therapies: 3D Bubble Representation
Figure 8.3. In Silico Drug Discovery Service Providers for Gene Therapies: 3D Bubble Representation
Figure 8.4. In Silico Drug Discovery Service Providers for Nucleic Acids: 3D Bubble Representation
Figure 8.5. In Silico Drug Discovery Service Providers for Peptides: 3D Bubble Representation
Figure 8.6. In Silico Drug Discovery Service Providers for Proteins: 3D Bubble Representation
Figure 8.7. In Silico Drug Discovery Service Providers for Vectors 3D Bubble Representation
Figure 9.1. In Silico Drug Discovery Service Providers: Popular Strategies or Business Models
Figure 10.1. Small Molecule and Large Molecule Drugs: Historical Trend of FDA Approval (2005-2019)
Figure 10.2. Small Molecules versus Large Molecules: Comparison of Key Characteristics
Figure 10.3. Small Molecules versus Large Molecules: Comparison of Manufacturing Process
Figure 11.1. Survey Insights: Distribution of Respondents by Year of Establishment of Company
Figure 11.2. Survey Insights: Distribution of Respondents by Company Size
Figure 11.3. Survey Insights: Distribution of Respondents by Location of Company Headquarters (Continent-Wise)
Figure 11.4. Survey Insights: Distribution of Respondents by Location of Company Headquarters (Country-Wise)
Figure 11.5. Survey Insights: Distribution by Designation and Seniority Level of Respondents
Figure 11.6. Survey Insights: Distribution by Drug Discovery Steps
Figure 11.7. Survey Insights: Distribution by Type of Large Molecule
Figure 11.8. Survey Insights: Distribution by In Silico-based Service Portfolio
Figure 11.9. Survey Insights: Distribution by Likely Adoption of In Silico Tools
Figure 11.10. Survey Insights: Distribution by Current Market Opportunity
Figure 11.11. Survey Insights: Distribution by Likely Growth Rate
Figure 11.12. Survey Insights: Distribution by Likely Cost Reduction using In Silico Tools in Large Molecule Drug Discovery
Figure 12.1. Overall Cost Saving Potential of In Silico Tools in Large Molecule Drug Discovery: Growth Scenarios
Figure 12.2. Overall Cost Saving Potential of In Silico Tools in Large Molecule Drug Discovery, 2020-2030 (USD Billion)
Figure 13.1. In Silico Drug Discovery Services Market for Large Molecules: Methodology and Key Assumptions
Figure 13.2. Overall In Silico Drug Discovery Services Market for Large Molecules, 2020-2030 (USD Million)
Figure 13.3. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Drug Discovery Steps, 2020 and 2030 (USD Million)
Figure 13.4. In Silico Drug Discovery Services Market for Large Molecules for Target Identification, 2020-2030 (USD Million)
Figure 13.5. In Silico Drug Discovery Services Market for Large Molecules for Target Validation, 2020-2030 (USD Million)
Figure 13.6. In Silico Drug Discovery Services Market for Large Molecules for Hit Generation, 2020-2030 (USD Million)
Figure 13.7. In Silico Drug Discovery Services Market for Large Molecules for Hit-to-Lead, 2020-2030 (USD Million)
Figure 13.8. In Silico Drug Discovery Services Market for Large Molecules for Lead Optimization, 2020-2030 (USD Million)
Figure 13.9. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Type of Large Molecule, 2020 and 2030 (USD Million)
Figure 13.10. In Silico Drug Discovery Services Market for Large Molecules for Antibodies, 2020-2030 (USD Million)
Figure 13.11. In Silico Drug Discovery Services Market for Large Molecules for Proteins, 2020-2030 (USD Million)
Figure 13.12. In Silico Drug Discovery Services Market for Large Molecules for Peptides, 2020-2030 (USD Million)
Figure 13.13. In Silico Drug Discovery Services Market for Large Molecules for Nucleic Acid, 2020-2030 (USD Million)
Figure 13.14. In Silico Drug Discovery Services Market for Large Molecules for Vectors, 2020-2030 (USD Million)
Figure 13.15. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Company Size, 2020 and 2030 (USD Million)
Figure 13.16. In Silico Drug Discovery Services Market for Large Molecules for Small Companies, 2020-2030 (USD Million)
Figure 13.17. In Silico Drug Discovery Services Market for Large Molecules for Mid-sized Companies, 2020-2030 (USD Million)
Figure 13.18. In Silico Drug Discovery Services Market for Large Molecules for Large Companies, 2020-2030 (USD Million)
Figure 13.19. In Silico Drug Discovery Services Market for Large Molecules: Market Attractiveness Analysis by Type of Therapeutic Area, 2020 and 2030 (USD Million)
Figure 13.20. In Silico Drug Discovery Services Market for Large Molecules for Autoimmune Disorders, 2020-2030 (USD Million)
Figure 13.21. In Silico Drug Discovery Services Market for Large Molecules for Blood Disorders, 2020-2030 (USD Million)
Figure 13.22. In Silico Drug Discovery Services Market for Large Molecules for Cardiovascular Disorders, 2020-2030 (USD Million)
Figure 13.23. In Silico Drug Discovery Services Market for Large Molecules for Gastrointestinal and Digestive Disorders, 2020-2030 (USD Million)
Figure 13.24. In Silico Drug Discovery Services Market for Large Molecules for Hormonal Disorders, 2020-2030 (USD Million)
Figure 13.25. In Silico Drug Discovery Services Market for Large Molecules for HIV / AIDS, 2020-2030 (USD Million)
Figure 13.26. In Silico Drug Discovery Services Market for Large Molecules for Infectious Diseases, 2020-2030 (USD Million)
Figure 13.27. In Silico Drug Discovery Services Market for Large Molecules for Metabolic Disorders, 2020-2030 (USD Million)
Figure 13.28. In Silico Drug Discovery Services Market for Large Molecules for Mental Disorders, 2020-2030 (USD Million)
Figure 13.29. In Silico Drug Discovery Services Market for Large Molecules for Musculoskeletal Disorders, 2020-2030 (USD Million)
Figure 13.30. In Silico Drug Discovery Services Market for Large Molecules for Neurological Disorders, 2020-2030 (USD Million)
Figure 13.31. In Silico Drug Discovery Services Market for Large Molecules for Oncological Disorders, 2020-2030 (USD Million)
Figure 13.32. In Silico Drug Discovery Services Market for Large Molecules for Respiratory Disorders, 2020-2030 (USD Million)
Figure 13.33. In Silico Drug Discovery Services Market for Large Molecules for Skin Disorders, 2020-2030 (USD Million)
Figure 13.34. In Silico Drug Discovery Services Market for Large Molecules for Urogenital Disorders, 2020-2030 (USD Million)
Figure 13.35. In Silico Drug Discovery Services Market for Large Molecules for Others, 2020-2030 (USD Million)
Figure 13.36. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Type of Sponsor, 2020 and 2030 (USD Million)
Figure 13.37. In Silico Drug Discovery Services Market for Large Molecules for Industry Players, 2020-2030 (USD Million)
Figure 13.38. In Silico Drug Discovery Services Market for Large Molecules for Non-Industry Players, 2020-2030 (USD Million)
Figure 13.39. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Key Geographical Regions, 2020 and 2030 (USD Million)
Figure 13.40. In Silico Drug Discovery Services Market for Large Molecules in North America, 2020 and 2030 (USD Million)
Figure 13.41. In Silico Drug Discovery Services Market for Large Molecules in the US, 2020- 2030 (USD Million)
Figure 13.42. In Silico Drug Discovery Services Market for Large Molecules in Canada, 2020-2030 (USD Million)
Figure 13.43. In Silico Drug Discovery Services Market for Large Molecules in Europe, 2020 and 2030 (USD Million)
Figure 13.44. In Silico Drug Discovery Services Market for Large Molecules in Germany, 2020-2030 (USD Million)
Figure 13.45. In Silico Drug Discovery Services Market for Large Molecules in France, 2020-2030 (USD Million)
Figure 13.46. In Silico Drug Discovery Services Market for Large Molecules in the UK, 2020-2030 (USD Million)
Figure 13.47. In Silico Drug Discovery Services Market for Large Molecules in Italy, 2020-2030 (USD Million)
Figure 13.48. In Silico Drug Discovery Services Market for Large Molecules in Spain, 2020-2030 (USD Million)
Figure 13.49. In Silico Drug Discovery Services Market for Large Molecules in Rest of Europe, 2020-2030 (USD Million)
Figure 13.50. In Silico Drug Discovery Services Market for Large Molecules in Asia-Pacific and Rest of the World, 2020 and 2030 (USD Million)
Figure 13.51. In Silico Drug Discovery Services Market for Large Molecules in China, 2020-2030 (USD Million)
Figure 13.52. In Silico Drug Discovery Services Market for Large Molecules in India, 2020-2030 (USD Million)
Figure 13.53. In Silico Drug Discovery Services Market for Large Molecules in Japan, 2020-2030 (USD Million)
Figure 14.1. Upcoming Trends in Drug Discovery: Future Growth Opportunities
List Of Tables
Table 4.1. In Silico Drug Discovery Service Providers for Large Molecules: List of Industry Players
Table 4.2. In Silico Drug Discovery Services for Large Molecules: Information on Drug Discovery Steps
Table 4.3. In Silico Drug Discovery Service Providers for Large Molecules: Information on Type of In Silico Approach
Table 4.4. In Silico Drug Discovery Service Providers for Large Molecules: Information on Type of Clienetle
Table 4.5. In Silico Drug Discovery Services for Large Molecules: Information on Type of Large Molecule
Table 4.6. In Silico Drug Discovery Services for Large Molecules: Information on In Silico-based Service Offerings
Table 4.7. In Silico Drug Discovery Services for Large Molecules: Additional Information
Table 4.8. In Silico Drug Discovery Services: List of Software / Technologies
Table 4.9. In Silico Drug Discovery Services: List of Consulting and Training Service Providers
Table 6.1. In Silico Service Providers: List of Companies Profiled
Table 6.2. BioDuro: Key Highlights
Table 6.3. BioDuro: List of Funding Instances and Investors
Table 6.4. BioDuro: Recent Developments and Future Outlook
Table 6.5. Creative Biostructure: Key Highlights
Table 6.6. Creative Biostructure: List of Funding Instances and Investors
Table 6.7. Creative Biostructure: Recent Developments and Future Outlook
Table 6.8. GenScript: Key Highlights
Table 6.9. GenScript: List of Funding Instances and Investors
Table 6.10. GenScript: Recent Developments and Future Outlook
Table 6.11. LakePharma: Key Highlights
Table 6.12. LakePharma: List of Funding Instances and Investors
Table 6.13. LakePharma: Recent Developments and Future Outlook
Table 6.14. Abzena: Key Highlights
Table 6.15. Abzena: List of Funding Instances and Investors
Table 6.16. Abzena: Recent Developments and Future Outlook
Table 6.17. BioNTech: Key Highlights
Table 6.18. BioNTech: List of Funding Instances and Investors
Table 6.19. BioNTech: Recent Developments and Future Outlook
Table 6.20. Sygnature Discovery: Key Highlights
Table 6.21. Sygnature Discovery: List of Funding Instances and Investors
Table 6.22. Sygnature Discovery: Recent Developments and Future Outlook
Table 6.23. ChemPartner: Key Highlights
Table 6.24. ChemPartner: Recent Developments and Future Outlook
Table 6.25. Sundia MediTech: Key Highlights
Table 6.26. Sundia MediTech: List of Funding Instances and Investors
Table 6.27. Sundia MediTech: Recent Developments and Future Outlook
Table 6.28. Viva Biotech: Key Highlights
Table 6.29. Viva Biotech: List of Funding Instances and Investors
Table 6.30. Viva Biotech: Recent Developments and Future Outlook
Table 10.1. Comparison of Strengths and Weaknesses of Small Molecules and Large Molecules
Table 10.2. Comparison of Development Characteristics of Small Molecules and Large Molecules
Table 10.3. Challenges in the Discovery of Different Types of Large Molecules
Table 11.1. Survey Insights: Overview of Respondents
Table 11.2. Survey Insights: Designation and Seniority Levels
Table 11.3. Survey Insights: Distribution by Drug Discovery Steps
Table 11.4. Survey Insights: Distribution by Type of Large Molecule
Table 11.5. Survey Insights: Distribution by In Silico-based Service Portfolio
Table 11.6. Survey Insights: Distribution by Likely Adoption of In Silico Tools
Table 11.7. Survey Insights: Distribution by Current Market Opportunity
Table 11.8. Survey Insights: Distribution by Likely Growth Rate
Table 11.9. Survey Insights: Distribution by Likely Cost Reduction using In Silico Tools in Large Molecule Drug Discovery
Table 12.1. Likely Cost Reduction using In Silico Services for Large Molecules
Table 12.2 Drug Discovery Steps: Key Parameters
Table 14.1. Companies Offering Artificial Intelligence and In Silico Services
Table 14.2. Companies Offering Cloud Computing Platforms and In Silico Services
Table 15.1. Conifer Point Pharmaceuticals: Company Snapshot
Table 15.2. candidum: Company Snapshot
Table 15.3. Evotec: Company Snapshot
Table 15.4. ProSciens: Company Snapshot
Table 16.1. In Silico Drug Discovery Services for Large Molecules: Distribution by Year of Establishment
Table 16.2. In Silico Drug Discovery Services for Large Molecules: Distribution by Company Size
Table 16.3. In Silico Drug Discovery Services for Large Molecules: Distribution by Location of Headquarters
Table 16.4. In Silico Drug Discovery Services for Large Molecules: Distribution by Type of Business Model
Table 16.5. In Silico Drug Discovery Services for Large Molecules: Distribution by Drug Discovery Steps
Table 16.6. In Silico Drug Discovery Services for Large Molecules: Distribution by Type of Large Molecule
Table 16.7. In Silico Drug Discovery Services for Large Molecules: Distribution by Type of Antibody
Table 16.8. In Silico Drug Discovery Services for Large Molecules: Distribution by Type of Protein
Table 16.9. In Silico Drug Discovery Services for Large Molecules: Distribution by Type of Designing Approach Used
Table 16.10. In Silico Drug Discovery Services for Large Molecules: Distribution by In Silico Service Offering
Table 16.11. Small Molecule and Large Molecule Drugs: Historical Trend of FDA Approval (2005 - 2019)
Table 16.12. Survey Insights: Distribution of Respondents by Year of Establishment of Company
Table 16.13. Survey Insights: Distribution of Respondents by Employee Size
Table 16.14. Survey Insights: Distribution of Respondents by Location of Company Headquarters (Continent-Wise)
Table 16.15. Survey Insights: Distribution of Respondents by Location of Company Headquarters (Country-Wise)
Table 16.16. Survey Insights: Distribution by Designation and Seniority Level of Respondents
Table 16.17. Survey Insights: Distribution by Drug Discovery Steps
Table 16.18. Survey Insights: Distribution by Type of Large Molecule
Table 16.19. Survey Insights: Distribution by In Silico-based Service Portfolio
Table 16.20. Survey Insights: Distribution by Likely Adoption of In Silico Tools
Table 16.21. Survey Insights: Distribution by Current Market Opportunity
Table 16.22. Survey Insights: Distribution by Likely Growth Rate
Table 16.23. Survey Insights: Distribution by Likely Cost Reduction using In Silico Tools in Large Molecule Drug Discovery
Table 16.24. Overall Cost Saving Potential of In Silico Tools in Large Molecule Drug Discovery, 2020-2030 (USD Billion)
Table 16.25. Overall In Silico Drug Discovery Services Market for Large Molecules, 2020-2030 (USD Million)
Table 16.26. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Drug Discovery Steps, 2020 and 2030 (USD Million)
Table 16.27. In Silico Drug Discovery Services Market for Large Molecules for Target Identification, 2020-2030 (USD Million)
Table 16.28. In Silico Drug Discovery Services Market for Large Molecules for Target Validation, 2020-2030 (USD Million)
Table 16.29. In Silico Drug Discovery Services Market for Large Molecules for Hit Generation, 2020-2030 (USD Million)
Table 16.30. In Silico Drug Discovery Services Market for Large Molecules for Hit-to-Lead,- 2020-2030 (USD Million)
Table 16.31. In Silico Drug Discovery Services Market for Large Molecules for Lead Optimization, 2020-2030 (USD Million)
Table 16.32. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Type of Large Molecule, 2020 and 2030 (USD Million)
Table 16.33. In Silico Drug Discovery Services Market for Large Molecules for Antibodies, 2020-2030 (USD Million)
Table 16.34. In Silico Drug Discovery Services Market for Large Molecules for Proteins, 2020-2030 (USD Million)
Table 16.35. In Silico Drug Discovery Services Market for Large Molecules for Peptides, 2020-2030 (USD Million)
Table 16.36. In Silico Drug Discovery Services Market for Large Molecules for Nucleic Acid, 2020-2030 (USD Million)
Table 16.37. In Silico Drug Discovery Services Market for Large Molecules for Vectors, 2020-2030 (USD Million)
Table 16.38. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Company Size, 2020 and 2030 (USD Million)
Table 16.39. In Silico Drug Discovery Services Market for Large Molecules for Small Companies, 2020-2030 (USD Million)
Table 16.40. In Silico Drug Discovery Services Market for Large Molecules for Mid-sized Companies, 2020-2030 (USD Million)
Table 16.41. In Silico Drug Discovery Services Market for Large Molecules for Large Companies, 2020-2030 (USD Million)
Table 16.42. In Silico Drug Discovery Services Market for Large Molecules for Autoimmune Disorders, 2020-2030 (USD Million)
Table 16.43. In Silico Drug Discovery Services Market for Large Molecules for Blood Disorders, 2020-2030 (USD Million)
Table 16.44. In Silico Drug Discovery Services Market for Large Molecules for Cardiovascular Disorders, 2020-2030 (USD Million)
Table 16.45. In Silico Drug Discovery Services Market for Large Molecules for Gastrointestinal and Digestive Disorders, 2020-2030 (USD Million)
Table 16.46. In Silico Drug Discovery Services Market for Large Molecules for Hormonal Disorders, 2020-2030 (USD Million)
Table 16.47. In Silico Drug Discovery Services Market for Large Molecules for HIV / AIDS, 2020-2030 (USD Million)
Table 16.48. In Silico Drug Discovery Services Market for Large Molecules for Infectious Diseases, 2020-2030 (USD Million)
Table 16.49. In Silico Drug Discovery Services Market for Large Molecules for Metabolic Disorders, 2020-2030 (USD Million)
Table 16.50. In Silico Drug Discovery Services Market for Large Molecules for Mental Disorders, 2020-2030 (USD Million)
Table 16.51. In Silico Drug Discovery Services Market for Large Molecules for Musculoskeletal Disorders, 2020-2030 (USD Million)
Table 16.52. In Silico Drug Discovery Services Market for Large Molecules for Neurological Disorders, 2020-2030 (USD Million)
Table 16.53. In Silico Drug Discovery Services Market for Large Molecules for Oncological Disorders, 2020-2030 (USD Million)
Table 16.54. In Silico Drug Discovery Services Market for Large Molecules for Respiratory Disorders, 2020-2030 (USD Million)
Table 16.55. In Silico Drug Discovery Services Market for Large Molecules for Skin Disorders, 2020-2030 (USD Million)
Table 16.56. In Silico Drug Discovery Services Market for Large Molecules for Urogenital Disorders, 2020-2030 (USD Million)
Table 16.57. In Silico Drug Discovery Services Market for Large Molecules for Others, 2020-2030 (USD Million)
Table 16.58. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Type of Sponsor, 2020 and 2030 (USD Million)
Table 16.59. In Silico Drug Discovery Services Market for Large Molecules for Industry Players, 2020-2030 (USD Million)
Table 16.60. In Silico Drug Discovery Services Market for Large Molecules for Non-Industry Players, 2020-2030 (USD Million)
Table 16.61. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Key Geographical Regions, 2020 and 2030 (USD Million)
Table 16.62. In Silico Drug Discovery Services Market for Large Molecules in North America, 2020 and 2030 (USD Million)
Table 16.63. In Silico Drug Discovery Services Market for Large Molecules in the US, 2020- 2030 (USD Million)
Table 16.64. In Silico Drug Discovery Services Market for Large Molecules in Canada, 2020-2030 (USD Million)
Table 16.65. In Silico Drug Discovery Services Market for Large Molecules in Europe, 2020 and 2030 (USD Million)
Table 16.66. In Silico Drug Discovery Services Market for Large Molecules in Germany, 2020-2030 (USD Million)
Table 16.67. In Silico Drug Discovery Services Market for Large Molecules in France, 2020-2030 (USD Million)
Table 16.68. In Silico Drug Discovery Services Market for Large Molecules in the UK, 2020-2030 (USD Million)
Table 16.69. In Silico Drug Discovery Services Market for Large Molecules in Italy, 2020-2030 (USD Million)
Table 16.70. In Silico Drug Discovery Services Market for Large Molecules in Spain, 2020-2030 (USD Million)
Table 16.71. In Silico Drug Discovery Services Market for Large Molecules in Rest of Europe, 2020-2030 (USD Million)
Table 16.72. In Silico Drug Discovery Services Market for Large Molecules in Asia-Pacific and Rest of the World, 2020 and 2030 (USD Million)
Table 16.73. In Silico Drug Discovery Services Market for Large Molecules in China, 2020-2030 (USD Million)
Table 16.74. In Silico Drug Discovery Services Market for Large Molecules in India, 2020-2030 (USD Million)
Table 16.75. In Silico Drug Discovery Services Market for Large Molecules in Japan, 2020-2030 (USD Million)
